Welcome to DoctoRx Unscripted — where doctors shaping the next chapter of patient care come together for raw, real, and rigorously scientific conversations at the heart of medicine. Hosted by Dr. Tania Small, SVP of Global Medical Affairs — a physician who has dedicated her career to turning breakthrough science into real-world patient impact. In each episode, Dr. Small sits down with the world’s leading minds in medicine to dive into the breakthroughs, surface the unspoken realities, and tackle the real-world challenges shaping tomorrow’s standard of care.
No soundbites. No scripts.
Just evidence-based, peer-to-peer conversations that challenge thinking, ignite innovation, and equip you with insights to transform your own practice. So whether you’re in the clinic, the lab, or the boardroom — join us to rewrite patient care.
Unscripted. Unfiltered. Unapologetic.
Beyond the Tumor: From Evidence to Action – Part 2
Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for Part 2 of this DoctoRx Unscripted conversation exploring how biology-based behavior change is redefining cancer care.In Part 2, Dr. Small hosts Arianna Huffington, Founder and CEO of Thrive Global, and Chris Boerner, Board Chair and CEO of Bristol Myers Squibb, for a candid discussion on moving beyond treating the tumor to delivering true whole-person care.Together, they explore:
How everyday factors, like sleep, stress, movement, and social connection, impact cancer care
Simple steps to reinforce healthier daily routines
Why lifestyle changes remain critical alongside medical therapies
How pharma leaders can integrate behavioral metrics into clinical trials
Strategies to overcome healthcare disparities and expand access to behavioral health tools
Medicines and healthy behaviors achieve more together than either can alone. Tune in to see why placing the patient at the center of oncology care can drive better long-term outcomes.
22 Sept 2026
Beyond the Tumor: From Biology to Behavior – Part 1
Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for Part 1 of a timely DoctoRx Unscripted conversation with Dr. Neil Iyengar, board-certified medical oncologist and Director of Survivorship Services at Winship Cancer Institute of Emory University.Together, they examine how metabolism, body composition, the gut microbiome, stress, and sleep influence cancer risk, treatment response, and long-term survivorship.In this episode, Dr. Small and Dr. Iyengar discuss:
Why muscle-to-fat ratio matters more than BMI for health and cancer risk
The connection between gut health, fiber, and cancer treatment success
What new research reveals about GLP-1s in oncology
How clinicians can make tailored exercise and nutrition accessible to every patient
Learn how targeted lifestyle interventions pair with precision oncology.
20 May 2026
Lung Cancer – No Longer the Disease We Once Thought It Was
Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a forward-looking episode of DoctoRx Unscripted, featuring leading thoracic oncologists Dr. Christine Lovly and Dr. Nate Pennell.Together, they examine innovations redefining what’s possible for patients with lung cancer:
Biomarker-driven therapy and molecular profiling;
Liquid biopsy and ctDNA testing;
AI-assisted detection and radiomics; and
Next-generation immunotherapies, including bispecifics, T-cell engagers, and personalized vaccines.
They also share their perspectives on a critical challenge: translating scientific progress into real-world impact by expanding access and closing gaps in care.If you're working to advance oncology care—or interested in deepening your understanding of what’s shaping its future—this is a conversation you don’t want to miss.
25 Feb 2026
Part 3 - Hypertrophic Cardiomyopathy: Hidden in Plain Sight
Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a special edition of DoctoRx Unscripted, focused on hypertrophic cardiomyopathy (HCM)—one of the most common inherited cardiac diseases and one of the most frequently missed.
In Part 3, Dr. Small sits down with patient advocate Lisa Salberg, founder of the Hypertrophic Cardiomyopathy Association (HCMA), to explore how a personal diagnosis evolved into a global movement—helping to establish more than 60 Centers of Excellence around the world.
The conversation reinforces why embedding the patient voice early is essential to advancing cardiovascular medicine.
25 Feb 2026
Part 2 - Hypertrophic Cardiomyopathy: Hidden in Plain Sight
Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a special edition of DoctoRx Unscripted, focused on hypertrophic cardiomyopathy (HCM)—one of the most common inherited cardiac diseases and one of the most frequently missed.
In Part 2, Dr. Small welcomes HCM expert Dr. Matthew Martinez and leading cardiologist Dr. Nani Bhalla. Together, they examine why hypertrophic cardiomyopathy has historically been so difficult to detect—and what has changed in recent years to begin altering that trajectory.
The discussion explores how earlier recognition, paired with more precise and individualized treatment decisions, can change outcomes in meaningful and lasting ways.
25 Feb 2026
Part 1 - Hypertrophic Cardiomyopathy: Hidden in Plain Sight
Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a special edition of DoctoRx Unscripted, focused on hypertrophic cardiomyopathy (HCM)—one of the most common inherited cardiac diseases and one of the most frequently missed.
In Part 1, NFL tight end Tommy Sweeney shares his experience of being diagnosed with HCM. He reflects on his personal journey— from diagnosis and treatment decision making to his return to the NFL with his condition appropriately treated and well managed.
His story underscores a sobering reality: HCM can remain undetected even in individuals who receive frequent medical screenings, like elite athletes.
3 Dec 2025
Part 2 - Myeloma: The New Playbook
The Future of Myeloma Care: In the concluding conversation, Dr. Small and her guests look beyond today’s therapies to the innovations shaping tomorrow. From early detection and prevention to next-generation platforms and therapies, the discussion traces how biology, technology, and compassion are converging to change lives. They challenge outdated dogmas, champion smarter, safer treatment strategies, and remind us who this fight is truly for: the patients, families, and next generation of clinicians carrying the mission forward.
3 Dec 2025
Part 1 - Myeloma: The New Playbook
The Bleeding Edge of Discovery: What does the next decade of myeloma care look like? In this first installment, Dr. Tania Small brings together three of the world’s foremost experts to explore the breakthroughs redefining hope in multiple myeloma. From minimal residual disease (MRD) as a new regulatory endpoint to the research of immune-based therapies and the transformative potential these may hold, the panel dissects how science is accelerating toward the possibility of a functional cure. They also tackle some of the field’s toughest questions: how to sequence therapy in an era of quads, bispecifics, and antibody-drug conjugates, and how to close the survival gap for underrepresented populations by translating biology into equitable access.
16 Oct 2025
Colorectal Cancer: The Hidden Drivers
Dr. Tania Small sits down with Dr. Heinz-Josef Lenz, one of the world’s greatest minds in gastrointestinal medical research, for a thought-provoking conversation on the future of colorectal cancer (CRC) care.
Together, they unpack the rising incidence of early-onset CRC and the factors driving the surge of new cases in younger patients. This conversation dives into cutting-edge innovations that are reshaping detection and treatment:
• ctDNA liquid biopsies and minimal residual disease testing - revolutionizing how relapse is detected.
• Next-generation diagnostics and precision screening, including AI-assisted colonoscopies - enabling earlier, more accurate identification.
• Methylation profiling, tumor microenvironment and epigenetic therapies - advancing personalized therapy and novel treatments.
• Immunotherapies and targeted agents - moving to the “front line” with the potential to transform treatment approaches into organ-preserving strategies.
But the conversation doesn’t stop at science. Together, they examine the influence of lifestyle, disparities in access, and patient-driven data on survival.
If you're driving change in oncology, this episode offers practical insights on integrating molecular testing, rethinking prevention, and preparing for the innovations ahead.
6 Aug 2025
ASCO® 2025: Cancer. Detected. Disrupted. Defied.
In this special edition of DoctoRx Unscripted, Dr. Tania Small sits down with three of the most visionary leaders in oncology, Dr. Lillian Siu, Dr. Fabrice André and Dr. Howard “Skip” Burris for a provocative conversation on data that has the potential to redefine the future of cancer care.
They unpack cutting-edge findings from ASCO® 2025-from next-generation diagnostics and novel modalities to AI-powered trials, precision medicine, prevention and what’s coming next in oncology innovation.
Dr. André, Dr. Burris and Dr. Siu are paid consultants for BMS.
20 Jun 2025
Part 2: Alzheimer’s beyond memory: Dr. Grossberg on psychosis & prevention
Dr. George Grossberg discusses Alzheimer's psychosis, novel therapeutic targets, and patient-driven research with Dr. Tania Small, highlighting innovative approaches to prevention in this interview.
20 Jun 2025
Part 1: Alzheimer’s on the edge: Dr. Grossberg on a new paradigm of care
Dr. George Grossberg discusses the early indicators of Alzheimer's disease, the impact of biomarkers, and the importance of equitable healthcare access for Alzheimer's patients in an interview with Dr. Tania Small.
22 May 2025
Unlocking Minds, Rewriting Futures: Dr. Ilan Melnick on Forensic Psychiatry & True Rehabilitation
Dr. Ilan Melnick discusses forensic psychiatry with Dr. Tania Small, exploring the complexities of criminal acts committed during psychotic episodes and paths toward genuine rehabilitation in this interview.
22 May 2025
Rewiring reality: Dr. John Kane on the future of schizophrenia care
Dr. Tania Small interviews Dr. John Kane about the future of schizophrenia care, exploring the biology of the illness, early psychosis, breakthroughs, and patient-driven science in treatment.
Who has been a guest on DoctoRx Unscripted
Names identified in recent episode analyses. Showing up to five guests.
Dr George Grossberg
Dr Ilan Melnick
Dr John Kane
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
5.0 / 5
11 ratings
Podcast Authority Score: 23 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
33
Social presence
0
YouTube
0
Engagement
32
Contact DoctoRx Unscripted
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Questions about DoctoRx Unscripted
Who hosts DoctoRx Unscripted?
Dr Tania Small host the show. Published by Bristol Myers Squibb.
How often do new episodes come out?
The show publishes monthly, based on its RSS feed.
Does DoctoRx Unscripted take guests?
Yes. Guests have been identified in episode analyses.
Host of DoctoRx Unscripted?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
